Safety and Efficacy of Venetoclax Combined With Rituximab, Ifosfamide, Carboplatin and Etoposide (Vicer) for Treatment of Relapsed Dlbcl: Final Results From the Phase 1trial

Hematological Oncology - United Kingdom
doi 10.1002/hon.141_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Safety and Efficacy of Atezolizumab, Obinutuzumab and Venetoclax Combination for Relapsed/Refractory Non-Hodgkin Lymphomas: Results From the Safety-Run of a Lysa Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bet Inhibitor Rg6146, Venetoclax, and Rituximab Is a Highly Active Regimen in Relapsed/Refractory (R/R) Dlbcl: Initial Report of Phase 1b Safety, Biomarker, and Response Data

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Allogeneic Transplantation After a Conditioning Regimen With Ifosfamide, Carboplatin and Etoposide (ICE)

Bone Marrow Transplantation
TransplantationHematology
1997English

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

High-Dose Chemotherapy With Carboplatin, Etoposide and Ifosfamide Followed by Autologous Stem Cell Rescue in Patients With Relapsed or Refractory Malignant Lymphomas: A Phase I/Ii Study

Bone Marrow Transplantation
TransplantationHematology
1997English

Dose Finding Study to Assess Safety, Pk and Efficacy of Fimepinostat (Cudc-907) With Venetoclax or Rituximab Plus Bendamustine in Patients With Relapsed/Refractory Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Addition of Lenalidomide to Rituximab, Ifosfamide, Carboplatin, Etoposide (RICER) in First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

British Journal of Haematology
Hematology
2014English

Final Results of a Phase 1b Study of the Safety and Efficacy of the PI3Kδ Inhibitor Acalisib (GS-9820) in Relapsed/Refractory Lymphoid Malignancies

Blood Cancer Journal
OncologyHematology
2018English

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy